Nitazoxanide
View Brand InformationWhat is Nitazoxanide?
Approved To Treat
Top Global Experts
Related Clinical Trials
Summary: The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols of this master protocol as appendices. Having one master protocol ensures different candidates are evaluated in the same consistent m...
Summary: Ulcerative colitis (UC) is a chronic inflammatory bowel Disease (IBD) that primarily affects the rectum and colon. The severity and persistence of mucosal inflammation are associated with morbidity and mortality.
Summary: The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19 to determine in-vivo antiviral activity. In this randomized open label, controlled, group sequential adaptive platform trial, we will assess the performance of three distinct types of intervention relative to control (no treatment):...
Related Latest Advances
Brand Information
Nitazoxanide tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum.
Nitazoxanide tablets have not been shown to be effective for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients [see

Nitazoxanide tablets should be taken with food.
Avoid concurrent warfarin use.
Rising Pharma Holdings, Inc.
East Brunswick, NJ 08816
ALINIA for Oral Suspension is distributed by Lupin Pharmaceuticals, Inc. under license from Romark.
PIR52603-05






